FindTrial
Sign In

intraperitoneal administration

PROCEDURE2 trials

Sponsors

Hijioka Susumu, University of Washington

Conditions

Fallopian Tube CancerOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid AdenocarcinomaOvarian Mixed Epithelial CarcinomaOvarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaPancreatic cancer without clinically distant metastasis Pancreatic cancer

Phase 1

Denileukin Diftitox Used in Treating Patients With Advanced Refractory Ovarian Cancer, Primary Peritoneal Carcinoma, or Epithelial Fallopian Tube Cancer
CompletedNCT00357448
University of WashingtonFallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma +8
Start: 2005-04-30Updated: 2019-05-14
64Cu-NCAB001 in patients with pancreatic cancer
RecruitingJPRN-jRCT2031230311
Hijioka SusumuPancreatic cancer without clinically distant metastasis Pancreatic cancer
Start: 2023-09-01Target: 18Updated: 2025-07-18

Related Papers

Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
2024-10-021 citations